-
Founded in:
1995-12-08 -
Country:
China -
Address:
No. 268, Minfeng Road, Wuzhong Economic Development Zone, Suzhou -
Tax NO.:
913205006283933800 -
Registered Funds:
$131.5 million -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefotaxime sodium |
A broad-spectrum third-generation cephalosporin with a low MIC, very stable to beta-lactamase, widely distributed in body fluids and various organs, with few side effects and good stability. It has strong antibacterial activity against Enterobacteriaceae, and both influenza bacilli and gonococci that produce and do not produce beta-lactamase are highly sensitive to this product. It has stronger antibacterial effects on Escherichia coli, aerogenes, various Proteus species, and influenza bacilli than second-generation cephalosporins. It has stronger activity against gram-positive cocci such as hemolytic streptococci and pneumococci.
More
A broad-spectrum third-generation cephalosporin with a low MIC, very stable to beta-lactamase, widely distributed in body fluids and various organs, with few side effects and good stability. It has strong antibacterial activity against Enterobacteriaceae, and both influenza bacilli and gonococci that produce and do not produce beta-lactamase are highly sensitive to this product. It has stronger antibacterial effects on Escherichia coli, aerogenes, various Proteus species, and influenza bacilli than second-generation cephalosporins. It has stronger activity against gram-positive cocci such as hemolytic streptococci and pneumococci. |
64485-93-4 | 45 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefpodoxime proxetil |
Cefpodoxime proxetil is an oral broad-spectrum third-generation cephalosporin. After entering the body, it is hydrolyzed into cefpodoxime by nonspecific esterase to exert antibacterial effects. It is effective against both Gram-positive and Gram-negative bacteria. It achieves bactericidal effects by inhibiting the biosynthesis of microbial cell walls. It is stable to β-lactamase and is still sensitive to many β-lactamase-producing microorganisms that are resistant to penicillin and cephalosporins.
More
Cefpodoxime proxetil is an oral broad-spectrum third-generation cephalosporin. After entering the body, it is hydrolyzed into cefpodoxime by nonspecific esterase to exert antibacterial effects. It is effective against both Gram-positive and Gram-negative bacteria. It achieves bactericidal effects by inhibiting the biosynthesis of microbial cell walls. It is stable to β-lactamase and is still sensitive to many β-lactamase-producing microorganisms that are resistant to penicillin and cephalosporins. |
87239-81-4 | 28 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| CeftazidiMe |
Bactericidal cephalosporin antibiotics work by inhibiting bacterial cell wall synthesis. Effective against a broad spectrum of Gram-positive and Gram-negative bacteria, resistant to most beta-lactamases, and sensitive to many pathogenic strains and pathogenic strains associated with hospital-acquired infections, including strains resistant to gentamicin and other aminoglycosides. When used in combination with aminoglycoside antibiotics in vitro, the efficacy is at least additive, and there is a clear synergistic effect against some strains.
More
Bactericidal cephalosporin antibiotics work by inhibiting bacterial cell wall synthesis. Effective against a broad spectrum of Gram-positive and Gram-negative bacteria, resistant to most beta-lactamases, and sensitive to many pathogenic strains and pathogenic strains associated with hospital-acquired infections, including strains resistant to gentamicin and other aminoglycosides. When used in combination with aminoglycoside antibiotics in vitro, the efficacy is at least additive, and there is a clear synergistic effect against some strains. |
72558-82-8 | 27 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Lansoprazole |
Extract from the above information
More
Extract from the above information |
103577-45-3 | 87 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Levamlodipine Besylate |
1. Calcium influx blocker, blocking extracellular calcium ions from entering myocardial and vascular smooth muscle cells through calcium ion channels in the cell membrane; 2. Directly relaxes vascular smooth muscle and has anti-hypertensive effects; 3. Dilates peripheral arterioles, reduces peripheral resistance (afterload), and reduces myocardial energy consumption and oxygen demand; 4. Dilates coronary arteries and coronary arterioles in normal and ischemic areas, increasing myocardial oxygen supply; 5. It takes a long time to metabolize in the liver, so it should be used with caution when liver function is impaired.
More
1. Calcium influx blocker, blocking extracellular calcium ions from entering myocardial and vascular smooth muscle cells through calcium ion channels in the cell membrane; 2. Directly relaxes vascular smooth muscle and has anti-hypertensive effects; 3. Dilates peripheral arterioles, reduces peripheral resistance (afterload), and reduces myocardial energy consumption and oxygen demand; 4. Dilates coronary arteries and coronary arterioles in normal and ischemic areas, increasing myocardial oxygen supply; 5. It takes a long time to metabolize in the liver, so it should be used with caution when liver function is impaired. |
150566-71-5 | 0 |